What are the Canadian guidelines for prescribing tadalafil for erectile dysfunction in adult men?

Canadian Guidelines for Tadalafil Use in Erectile Dysfunction

While no specific Canadian guidelines were identified in the provided evidence, tadalafil should be offered as first-line pharmacotherapy for erectile dysfunction in adult men, with dosing options of either 10 mg as-needed (titrated between 5-20 mg) or 2.5-5 mg once daily, unless contraindicated. 1, 2

Dosing Regimens

As-Needed (PRN) Dosing

• Starting dose: 10 mg taken at least 30 minutes prior to anticipated sexual activity 2
• Titrate based on efficacy and tolerability:
  • Increase to 20 mg if inadequate response
  • Decrease to 5 mg if side effects problematic
• Maximum frequency: Once per day 2
• Duration of action: Up to 36 hours 2
• Sexual stimulation is required for efficacy 1

Once Daily Dosing

• Starting dose: 2.5 mg taken at approximately the same time daily 2
• May increase to 5 mg based on individual response 2
• Key advantage: Allows spontaneous sexual activity without timing medication 2
• Evidence shows comparable or superior efficacy to PRN dosing, particularly in men with partial response to PRN PDE5 inhibitors 3, 4, 5

Clinical Decision-Making Algorithm

Choose Once Daily (2.5-5 mg) if:

• Patient desires spontaneous sexual activity without planning
• Previous incomplete response to PRN PDE5 inhibitors 4
• Concurrent benign prostatic hyperplasia (use 5 mg) 2
• Frequent sexual activity (≥2 times per week)

Choose PRN (10-20 mg) if:

• Infrequent sexual activity (<2 times per week)
• Patient preference for on-demand dosing
• Cost considerations (fewer tablets consumed)

Special Populations Requiring Dose Adjustment

Renal Impairment 2

PRN dosing:

• CrCl 30-50 mL/min: Start 5 mg, maximum 10 mg every 48 hours
• CrCl <30 mL/min or hemodialysis: Maximum 5 mg every 72 hours

Once daily dosing:

• CrCl 30-50 mL/min: Start 2.5 mg, may increase to 5 mg
• CrCl <30 mL/min or hemodialysis: Not recommended 2

Hepatic Impairment 2

• Mild-moderate (Child-Pugh A or B): Maximum 10 mg once daily for PRN; use caution with once daily dosing
• Severe hepatic disease: Generally not recommended

Concurrent Testosterone Deficiency

• Combination therapy with testosterone is more effective than tadalafil alone 1
• Testosterone monotherapy is ineffective for ED 1

Efficacy Expectations

Based on integrated data from 1913 patients 6:

• Mild ED: 54.3% (2.5 mg) and 74.8% (5 mg) achieve clinically important improvement
• Moderate ED: 51.3% (2.5 mg) and 63.1% (5 mg) achieve clinically important improvement
• Severe ED: 33.7% (2.5 mg) and 44.5% (5 mg) achieve clinically important improvement
• Men with diabetes and post-prostatectomy respond less robustly 1

Common Adverse Events 1

Most frequent (dose-dependent):

• Dyspepsia (lowest with avanafil among PDE5Is)
• Headache
• Flushing (lowest with tadalafil)
• Back pain
• Nasal congestion
• Myalgia
• Visual disturbance
• Dizziness

Critical Safety Warnings

Absolute Contraindications 2

• Concurrent nitrate use (any formulation)
• Recent cardiovascular events requiring activity restriction

Serious Adverse Events Requiring Immediate Attention 2

• Priapism: Erection >4 hours requires emergency evaluation
• Sudden vision loss: May indicate NAION (non-arteritic anterior ischemic optic neuropathy)
• Sudden hearing loss: May be accompanied by tinnitus and dizziness

Drug-Alcohol Interaction 2

• Substantial alcohol consumption (≥5 units) increases risk of orthostatic hypotension, dizziness, and headache
• Both act as mild vasodilators with additive effects

Common Pitfalls to Avoid

1. Inadequate trial before declaring failure: Multiple attempts needed; single dose insufficient to assess efficacy 1
2. Taking with large meals: May delay absorption and reduce efficacy 1
3. Lack of sexual stimulation: Medication requires sexual arousal to work 1
4. Premature dose escalation: Allow adequate trials at each dose level
5. Not addressing cardiovascular risk: ED is a risk marker for cardiovascular disease equivalent to smoking or family history of MI 1

Patient Counseling Essentials 2

• Sexual stimulation is necessary for efficacy
• PRN dosing: Take at least 30 minutes before activity; effective up to 36 hours
• Once daily: Take same time daily regardless of sexual activity timing
• Multiple attempts may be needed to establish efficacy
• Does not protect against sexually transmitted diseases
• Report erections lasting >4 hours immediately

Evidence Quality Note

The provided evidence consists primarily of American (AUA) 1 and European (EAU) 7 guidelines, along with FDA labeling 2. No specific Canadian guidelines were identified. However, the AUA guidelines from 2018 provide strong, evidence-based recommendations (Grade B-C evidence) that are widely applicable and consistent with international standards of care.